Concert Pharmaceuticals, Inc. (CNCE): Price and Financial Metrics

Concert Pharmaceuticals, Inc. (CNCE): $2.88

-0.07 (-2.37%)

POWR Rating

Component Grades













Add CNCE to Watchlist
Sign Up

Industry: Biotech


of 505

in industry


  • Sentiment is the dimension where CNCE ranks best; there it ranks ahead of 98.62% of US stocks.
  • CNCE's strongest trending metric is Momentum; it's been moving down over the last 49 weeks.
  • CNCE's current lowest rank is in the Momentum metric (where it is better than 7.05% of US stocks).

CNCE Stock Summary

  • Of note is the ratio of Concert Pharmaceuticals Inc's sales and general administrative expense to its total operating expenses; just 10.39% of US stocks have a lower such ratio.
  • Revenue growth over the past 12 months for Concert Pharmaceuticals Inc comes in at 422.52%, a number that bests 98.09% of the US stocks we're tracking.
  • In terms of volatility of its share price, CNCE is more volatile than 96.34% of stocks we're observing.
  • If you're looking for stocks that are quantitatively similar to Concert Pharmaceuticals Inc, a group of peers worth examining would be CARA, RCUS, KLDO, ANAB, and DTIL.
  • CNCE's SEC filings can be seen here. And to visit Concert Pharmaceuticals Inc's official web site, go to

CNCE Valuation Summary

  • In comparison to the median Healthcare stock, CNCE's EV/EBIT ratio is 100.68% lower, now standing at -0.2.
  • Over the past 92 months, CNCE's price/sales ratio has gone down 5.5.
  • Over the past 92 months, CNCE's price/sales ratio has gone down 5.5.

Below are key valuation metrics over time for CNCE.

Stock Date P/S P/B P/E EV/EBIT
CNCE 2021-08-31 3.6 1.0 -2.1 -0.2
CNCE 2021-08-30 3.5 0.9 -2.0 -0.1
CNCE 2021-08-27 3.6 1.0 -2.0 -0.2
CNCE 2021-08-26 3.5 1.0 -2.0 -0.1
CNCE 2021-08-25 3.5 1.0 -2.0 -0.1
CNCE 2021-08-24 3.4 0.9 -2.0 -0.1

CNCE Growth Metrics

  • Its 3 year cash and equivalents growth rate is now at 60.69%.
  • Its year over year net cashflow from operations growth rate is now at -10.21%.
  • The 5 year revenue growth rate now stands at -99.88%.
CNCE's revenue has moved down $33,199,000 over the prior 67 months.

The table below shows CNCE's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 33.53 -46.553 -58.542
2021-03-31 7.9 -71.917 -76.958
2020-12-31 7.902 -69.037 -74.766
2020-09-30 7.908 -67.885 -72.863
2020-06-30 6.417 -63.26 -71.14
2020-03-31 0.079 -65.257 -76.817

CNCE's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • CNCE has a Quality Grade of B, ranking ahead of 78.61% of graded US stocks.
  • CNCE's asset turnover comes in at 0.223 -- ranking 188th of 680 Pharmaceutical Products stocks.
  • SRNE, VBLT, and ISEE are the stocks whose asset turnover ratios are most correlated with CNCE.

The table below shows CNCE's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.223 1 -0.784
2021-03-31 0.051 1 -0.738
2020-12-31 0.047 1 -0.595
2020-09-30 0.049 1 -0.584
2020-06-30 0.040 1 -0.577
2020-03-31 0.000 1 -0.647

CNCE Price Target

For more insight on analysts targets of CNCE, see our CNCE price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $15.33 Average Broker Recommendation 1.42 (Moderate Buy)

CNCE Stock Price Chart Interactive Chart >

Price chart for CNCE

CNCE Price/Volume Stats

Current price $2.88 52-week high $13.50
Prev. close $2.95 52-week low $2.84
Day low $2.86 Volume 59,300
Day high $2.96 Avg. volume 297,965
50-day MA $3.35 Dividend yield N/A
200-day MA $5.15 Market Cap 92.66M

Concert Pharmaceuticals, Inc. (CNCE) Company Bio

Concert Pharmaceuticals is a clinical stage biopharmaceutical company focused on applying its DCE Platform (deuterated chemical entity platform) to create novel small molecule drugs. The company was founded in 2006 and is based in Lexington, Massachusetts.

CNCE Latest News Stream

Event/Time News Detail
Loading, please wait...

CNCE Latest Social Stream

Loading social stream, please wait...

View Full CNCE Social Stream

Latest CNCE News From Around the Web

Below are the latest news stories about Concert Pharmaceuticals Inc that investors may wish to consider to help them evaluate CNCE as an investment opportunity.

The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs

Here''s a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 7) Alkermes plc (NASDAQ: ALKS ) Bicycle Therapeutics plc (NASDAQ: BCYC ) (announced interim Phase 1 data for BT5528 and preliminary results from Phase 1 study of BT8009) Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX ) Cytokinetics, Incorporated (NASDAQ: CYTK ) Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA ) Legend Biotech Corporation (NASDAQ: LEGN ) Click here for accessing Benzinga''s FDA Calendar Down In The Dumps (Biotech Stocks Hitting 52-week Lows Oct. 7) Acutus Medical, Inc. (NASDAQ: AFIB ) Adverum Biotechnologies, Inc. (NASDAQ: ADVM ) Akoya Biosciences, Inc. (NASDAQ: AKYA ) Amgen Inc. (NASDAQ: AMGN ) ( announced neurodegenerative disease drug...

Benzinga | October 8, 2021

We Think Concert Pharmaceuticals (NASDAQ:CNCE) Needs To Drive Business Growth Carefully

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Yahoo | September 22, 2021

Concert Pharmaceuticals to Present at Upcoming Investor Conferences

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #AlopeciaAreata--In September, Concert will present virtually at the HC Wainwright and Cantor healthcare conferences.

Business Wire | September 3, 2021

Landmarks and Bridges Will Illuminate Blue Throughout the Month of September for Alopecia Areata Awareness Month

LEXINGTON, Mass., August 31, 2021--Landmarks across the USA will light it up blue for alopecia areata awareness month, which is recognized annually during September.

Yahoo | August 31, 2021

Concert Pharmaceuticals Reports Second Quarter 2021 Financial Results

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #AlopeciaAreata--Concert reports financial results for the second quarter of 2021.

Business Wire | August 5, 2021

Read More 'CNCE' Stories Here

CNCE Price Returns

1-mo -22.37%
3-mo -14.54%
6-mo -31.26%
1-year -75.13%
3-year -81.09%
5-year -67.89%
YTD -77.22%
2020 37.02%
2019 -26.49%
2018 -51.49%
2017 151.41%
2016 -45.76%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8019 seconds.